A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial

Journal of Infection

Volumn 71, Issue 3, 2015, Pages 326-337

  Marsay, L ^a   Dold, C ^a   Green, C A ^a   Rollier, C S ^a   Norheim, G ^a   Sadarangani, M ^a   Shanyinde, M ^b   Brehony, C ^a   Thompson, A J ^a   Sanders, H ^c   Chan, H ^c   Haworth, K ^a   Derrick, J P ^d   Feavers, I M ^c   Maiden, M C ^a   Pollard, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

FetA; Molecular epidemiology; Neisseria meningitidis; Outer membrane vesicles; Vaccine

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; FETA PROTEIN; MENPF 1 VACCINE; OUTER MEMBRANE PROTEIN; PORIN A; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL SURFACE RECEPTOR; ENTEROBACTIN RECEPTOR; FRPB PROTEIN, BACTERIA; MENINGOCOCCUS VACCINE; PORIN; PORIN PROTEIN, NEISSERIA;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; MEMBRANE VESICLE; MENINGOCOCCEMIA; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; OUTER MEMBRANE VESICLE; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; SERUM BACTERICIDAL ANTIBODY ASSAY; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; IMMUNOLOGY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS; RECEPTORS, CELL SURFACE; SERUM BACTERICIDAL ANTIBODY ASSAY; YOUNG ADULT;

EID: 84942835617     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.05.006     Document Type: Article

References (53)

1. ECDC. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe 2007. ECDC; 2010.
2. Prevention Cf DCa. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2008. 2009.
3. England PH. Public Health England http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MeningococcalDisease/EpidemiologicalData/.
4. Rollier CS, Dold C, Marsay L, Sadarangani M, Pollard AJ. The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy. Expert Opin Biol Ther 2015;15(1):131-42
5. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2(8346):355-7
6. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126(5):514-21
7. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(Suppl. 2):B3-12
8. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14(2):195e207 [discussion 8e10].
9. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340(8827):1074-8
10. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailormade vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23(17e18):2191-6
11. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338(8775):1093-6
12. Caron F, Delbos V, Houivet E, Deghmane AE, Leroy JP, Hong E, et al. Evolution of immune response against Neisseria meningitidis B:14:P1.7, 16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine 2012;30(34):5059-62
13. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011;29(40):7100-6
14. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2, 4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol e CVI 2006;13(4):486-91
15. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012;30(Suppl. 2): B87-97
16. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013;31(23):2638-46
17. Derrick JP, Maiden MC, Feavers IM. Crystal structure of an Fab fragment in complex with a meningococcal serosubtype antigen and a protein G domain. J Mol Biol 1999;293(1):81-91
18. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004;10(4):674-8
19. Wedege E, Kuipers B, Bolstad K, van Dijken H, Frøholm LO, Vermont C, et al. Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect Immun 2003;71(7):3775-81
20. Ala'Aldeen DA, Davies HA, Borriello SP. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 1994;12(6): 535-41
21. Pettersson A, Kuipers B, Pelzer M, Verhagen E, Tiesjema RH, Tommassen J, et al. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific. Infect Immun 1990;58(9): 3036-41
22. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003;149(Pt 7):1849-58
23. van der Ley P, van der Biezen J, Sutmuller R, Hoogerhout P, Poolman JT. Sequence variability of FrpB, a major ironregulated outer-membrane protein in the pathogenic neisseriae. Microbiology 1996;142(Pt 11):3269-74
24. Kortekaas J, Muller SA, Ringler P, Gregorini M, Weynants VE, Rutten L, et al. Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA). Microbes Infect/Institut Pasteur 2006;8(8): 2145-53
25. Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol e CVI 2007; 14(7):830-8
26. Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998;66(7):3223-31
27. Tsai J, Dyer D, Sparling P. Loss of transferrin receptor activity in Neisseria meningitidis correlates with inability to use transferrin as an iron source. Infect Immun 1988;56(12):3132-8
28. Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Hoiby EA, et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine 2010;28(18):3211-8
29. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol Med 2001;66:81-107
30. Saleem M, Prince SM, Rigby SE, Imran M, Patel H, Chan H, et al. Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis. PLoS One 2013;8(2):e56746.
31. Hollander A, Mercante AD, Shafer WM, Cornelissen CN. The iron-repressed, AraC-like regulator MpeR activates expression of fetA in Neisseria gonorrhoeae. Infect Immun 2011;79(12): 4764-76
32. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004;72(10):5955-62
33. Brehony C, Trotter CL, Ramsay ME, Chandra M, Jolley KA, van der Ende A, et al. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development. Clin Vaccine Immunol e CVI 2014;21(6): 847-53
34. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007;31(1):15-26
35. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC. Molecular epidemiology of meningococcal disease in England and Wales 1975e1995, before the introduction of serogroup C conjugate vaccines. Microbiology 2008;154(Pt 4):1170-7
36. EU-IBIS. Invasive Neisseria meningitidis in Europe 2002. EUIBIS; December 2003. Report No.
37. HPA. Health protection weekly report. HPA; 22 February 2013. Report No.
38. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55(Pt 7):887-96
39. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14(2):67e79 [discussion 79e80].
40. Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. Meningococcal vaccines. Springer; 2001. p. 289-304
41. Sanders H, Norheim G, Chan H, Vipond C, Pollard AJ, Feavers I. Bactericidal FetA antibodies induced by an outer membrane vesicle vaccine derived from a serogroup B meningococcal isolate with constitutive FetA expression. PLoS One [Under review].
42. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006;24(9): 1395-400
43. Black JR, Dyer D, Thompson M, Sparling P. Human immune response to iron-repressible outer membrane proteins of Neisseria meningitidis. Infect Immun 1986;54(3):710-3
44. Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009;28(5): 385-90
45. Kimura A, Toneatto D, Kleinschmidt A, Wang HJ, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011; 18(3):483-6
46. Findlow J, Taylor S, Aase A, Horton R, Heyderman R, Southern J, et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun 2006;74(8):4557-65
47. Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Munoz A, et al. Persistence of antibodies in adolescents 18e24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccines Immunother 2013;9(11):2304-10
48. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outermembrane protein meningococcal vaccines: a randomized controlled trial in Chile. J Am Med Assoc 1999;281(16): 1520-7
49. Luijkx TA, van Dijken H, Hamstra H-J, Kuipers B, van der Ley P, van Alphen L, et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun 2003; 71(11):6367-71
50. Perkins B, Jonsdottir K, Briem H, Griffiths E, Plikaytis B, Hoiby E, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998;177(3): 683-91
51. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012;30(24):3710-6
52. Watkins ER, Maiden MC. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST Database. PLoS One 2012;7(9):e45349.
53. Weynants VE, Feron CM, Goraj KK, Bos MP, Denoel PA, Verlant VG, et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007;75(11): 5434-42